BURBANK, Calif., June 08, 2021 (World NEWSWIRE) — by using NewMediaWire — Medolife Rx, Inc. (“Medolife”), a worldwide integrated bioceutical company with R&D, manufacturing, and client product or service distribution, which is a the vast majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), now unveiled the next statement from management relating to the small business in lieu of its previously scheduled webcast on June 8, 2021.

“I would like to thank all of our valued shareholders for their desire in our company and continued excitement for exactly where we are headed. Just after examining the submitted inquiries and as we just held our Q1 2021 call, we realized that there had been, really, just a handful of goods that shareholders would like tackled. As such, we have made the decision to handle them in penned form to reach a larger viewers.

Very first, I would like to reiterate the standing of our pending pre-IND submission with the U.S. Food and Drug Administration (Food and drug administration). As most of you know, we have submitted the info that was requested in reaction to us from the Fda associated to the pre-IND submitting. The Food and drug administration then assigned us a case manager that has relayed that we can be expecting a additional reaction by mid-June, and we continue to count on this reaction on or all-around June 15. We continue to be incredibly optimistic on the submitting status and will update our shareholders all over the time of the reaction.

Further than our pharmaceutical initiatives, we have been closely targeted in the final couple of weeks on ramping up our nutraceutical division. I am happy to announce that we have finalized new branding that we will be rolling out in the coming months, less than the title Aelia. We chosen to go forward with a model identify modify after we have been knowledgeable that we could not trademark our beforehand declared new branding “QuantRx”. The name “Aelia” pays homage to our CEO, Dr. Arthur Mikaelian, the founder of the underlaying polarization technology. We will proceed to offer some of the great staple goods of Quanta, under the new branding although including new and definitely groundbreaking products and solutions in agony administration, natural beauty, and general wellness — all improved by the patented polarization engineering. We keep on to feel this technological innovation can make our items some of the most powerful and efficacious on the market place. In addition, we are working on finalizing some very remarkable celeb endorsement specials that we hope to announce in short order. Please stay tuned for updates on these endeavours in the in the vicinity of time period as we are just obtaining off the ground in this pretty interesting venture.

Next, a lot of of the issues submitted had to do with a new filing we created with the SEC. I would like to supply some added perception as to the intent of this filing and what it could indicate for the potential of our organization. The filing was a standard recognize of two proposed company steps: escalating the quantity of shares approved by the Company and giving authority to the Board of Directors for a probable reverse break up of our shares. Regarding the very first issue, it is significant to be aware that licensed and fantastic shares are different figures. Licensed refers to the overall feasible shares that could be issued, and remarkable refers to the overall selection of shares the firm has issued. Growing the amount of authorized shares did not instantly improve the amount of superb. We enhanced the number of approved shares to meet up with long run obligations to situation shares, be in a position to problem shares pursuant to a foreseeable future funding and to make it possible for us to have a sufficient variety of shares to make acquisitions or provide equity incentives.

With regards to the option to do a reverse split, I want to spotlight that this submitting gave authorization to our Board of Administrators to do a reverse split in the potential it did not specify how or when we would do this. We have still to come to a decision if or when we would need to have to do this nonetheless, again, like it in the submitting now gave us nonetheless yet another resource to benefit from to transfer to a increased trade in the long term. It did not established an genuine ratio that we would be held to, only a greatest allowable. We believe that obtaining our business outlined on other, far more notable exchanges, will ultimately lead to larger sized institutional desire and extensive-expression shareholder benefit. It was critical that we achieve this now, even though we plan for our potential.

Whilst I are not able to comment significantly on modern reactions from the market, I imagine it is critical to highlight that fluctuations have happened, which are owing to a multitude of factors, together with and further than the filing. I hope that our shareholders continue on to see the opportunity of our business strategy and the opportunity that executing on it generates. We work each and every day with their interests in intellect and are striving to make good conclusions that will make the extended-time period price of our Firm. That said, we welcome our shareholders to achieve out to a member of our IR team to discuss the organization and its filings in bigger depth.

Lastly, regarding inquiries relating to our fantastic convertible credit card debt, all of these numbers can be identified in our 10-K and 10-Q filings with the SEC, obtainable on their web site. Currently, we have close to just in excess of $600,000 of superb convertible financial debt, entered into by prior administration. We are getting steps to deal with this financial debt in a non-harmful way and hope to have an update on this shortly.

In closing, I would like to reiterate my sincerest thanks to people long-phrase shareholders who have ongoing to specific pleasure for our eyesight. Whilst some people today might not see what we are seeking to accomplish below, there are so numerous who do and that suggests the world to us. We have a initially-of-its-form technologies that has the opportunity to revolutionize the healthcare room, a sturdy clinical growth pipeline with items currently in the clinic, and a nutraceutical featuring that is 2nd to none. Our upcoming remains bright, and we have to preserve our eye on it.”

Sincerely,

Dr. Arthur Mikaelian

CEO, Medolife Rx

About Medolife Rx

Medolife Rx, Inc. is a world-wide biotechnology firm with operations in medical investigation, manufacturing, and consumer items. Medolife Rx was established by means of the merger of Medolife, a personal enterprise launched by Dr. Arthur Mikaelian who pioneered the unlaying polarization know-how that can make the Company’s portfolio of pharmaceutical and nutraceutical merchandise so helpful, and Quanta, Inc., a immediate-to-consumer wellness products portfolio corporation. The Company’s lead clinical development programs contain Escozine®, a proprietary formulation consisting of compact molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being investigated as a procedure of various indications, like COVID-19 and most cancers. The Organization has done preclinical protection and efficacy exploration on Escozine® and is pursuing solution registration and drug acceptance in various nations, together with the United States and all over Latin The usa.

Through its subsidiary QuantRx, Medolife manufactures and distributes client wellness merchandise in higher-effect purchaser spots such as agony reduction, elegance, and standard wellness. QuantRx products and solutions are designed employing Dr. Mikaelian’s polarization technologies, which applies improvements in quantum biology to maximize the efficiency of active substances. Eventually, Quanta’s mission is to provide much better, much more helpful components to elevate products efficacy, minimize squander, and aid much healthier, extra sustainable consumption.

Over and above its individual medical and client applications, the polarization technological innovation made use of by Medolife and its subsidiaries has a lot of likely applications. From potentiating bio-components, to making a lot more-successful carbon-trapping crops, to transformative anti-getting older answers, Medolife has the opportunity to upend how commercial and pharmaceutical merchandise are created and boost their gains, even though lowering their chemical focus.

Forward-Wanting Statements

Risk-free Harbor Assertion under the U.S. Non-public Securities Litigation Reform Act of 1995: This release consists of statements that are ahead-seeking in mother nature which categorical the beliefs and anticipations of management like statements relating to the Firm’s expected benefits of functions or liquidity statements about projections, predictions, expectations, estimates or forecasts as to our enterprise, economical and operational benefits and long run financial general performance and statements of management’s plans and targets and other identical expressions relating to matters that are not historical facts. In some cases, you can detect forward-seeking statements by terminology these as “foresee,” “estimate,” “prepare,” “task,” “continuing,” “ongoing,” “be expecting,” “we believe that,” “we intend,” “may well,” “will,” “should really,” “could,” and comparable expressions. This sort of statements are centered on latest strategies, estimates and expectations and entail a variety of regarded and unknown risks, uncertainties and other elements that could induce the Company’s future benefits, performance or achievements to vary appreciably from the effects, general performance or achievements expressed or implied by this kind of ahead-hunting statements. These aspects and supplemental details are mentioned in the Company’s filings with the Securities and Exchange Commission and statements in this launch should be evaluated in light of these crucial components. Whilst we think that these statements are based mostly upon reasonable assumptions, we can not guarantee long run outcomes. Ahead-looking statements speak only as of the day on which they are produced, and the Firm undertakes no obligation to update publicly or revise any ahead-wanting statement, irrespective of whether as a consequence of new data, upcoming developments or in any other case.

Contacts:

Tom Nelson

https://ir.quantrx.com/

480-326-8577

Kyle Porter

[email protected]

858-264-6600